This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola. At IQVIA Laboratories, we support infectious disease clinical trials with a variety of tools including:
- Niche and novel assay development
- DNA & RNA extraction and next-generation sequencing
- Integrated local lab data management services
- Global laboratory network held to rigorous quality standards and biosafety protocols
Download this white paper and learn how we are applying the latest technologies to provide insights for better management of infectious disease clinical trials. New diagnostics and therapies developed as a result can then be used against target pathogens and their resistant variants for improved safety.
Authors:
Ayaskant Pany, MD, Medical Laboratory Director and Scientific Advisor Tropical Diseases, Central Laboratories South Africa
Sorika van Niekerk, MSc, UP, SA, Senior Director/General Manager, Central Laboratories South Africa
Stephen Mortlock, DSc.
Wayne R. Hogrefe, Ph.D., D (ABMLI), Vice President, Vaccine unit
Complete the form below to access this white paper
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
